A study of amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1341-1349

  Wentzensen, Nicolas ^a   Gravitt, Patti E ^b   Solomon, Diane ^a   Wheeler, Cosette M ^c   Castle, Philip E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER GRADING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA TUMOR VIRUS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TARGET ORGANISM; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRIAGE; VAGINAL SMEARS;

EID: 66549102206     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1180     Document Type: Article

References (40)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370: 890-907. (Pubitemid 47371147)
2. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-434
3. Schiffman M, Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008;9:404-406
4. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111: 145-153 (Pubitemid 46982691)
5. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-1400 (Pubitemid 36741264)
6. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392 (Pubitemid 36741263)
7. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the highgrade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998;91:973-976 (Pubitemid 28246934)
8. Carozzi FM, Del MA, Confortini M, et al. Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting. Am J Clin Pathol 2005;124:716-721
9. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL. Interlaboratory reliability of hybrid capture 2. Am J Clin Pathol 2004; 122:238-245 (Pubitemid 38971357)
10. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006;24 Suppl 3:S3-78-S3/89. (Pubitemid 44293029)
11. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772 (Pubitemid 350137476)
12. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101 (Pubitemid 44116919)
13. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-1588 (Pubitemid 47598400)
14. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357:1589-1597 (Pubitemid 47598401)
15. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-222
16. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008;46:2595-2604
17. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. (Pubitemid 40450709)
18. Carozzi F, Bisanzi S, Sani C, et al. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364-369 (Pubitemid 46272047)
19. Mo LZ, Monnier-Benoit S, Kantelip B, et al. Comparison of AMPLICOR and hybrid capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA genotyping assay to screen the discordant results. J Clin Virol 2008; 41:104-110
20. Monsonego J, Bohbot JM, Pollini G, et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005;99:160-168 (Pubitemid 41354597)
21. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene hybrid capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007;45:2130-2137 (Pubitemid 47203782)
22. van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ. comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 2005;43:2662-2667 (Pubitemid 40827937)
23. Wahlstrom C, Iftner T, Dillner J, Dillner L. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 2007;79:1169-1175 (Pubitemid 47015417)
24. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361 (Pubitemid 30043317)
25. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183:1554-1564 (Pubitemid 32466692)
26. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol 2005;124:722-732 (Pubitemid 41532507)
27. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46:109-117
28. Schiffman M, Adrianza ME. ASCUS-LSIL triage study. Design, methods and characteristics of trial participants. Acta Cytol 2000;44: 726-742
29. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299 (Pubitemid 32219816)
30. Leisenring W, Pepe MS. Regression modeling of diagnostic likelihood ratios for the evaluation of medical diagnostic tests. Biometrics 1998;54:444-452 (Pubitemid 28262469)
31. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008;123:153-160
32. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-10119 (Pubitemid 44672065)
33. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between realtime polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:477-484 (Pubitemid 36713639)
34. Pretet JL, Dalstein V, Monnier-Benoit S, Delpeut S, Mougin C. High risk HPV load estimated by hybrid capture II correlates with HPV16 load measured by real-time PCR in cervical smears of HPV16- infected women. J Clin Virol 2004;31:140-147 (Pubitemid 39208954)
35. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92-100. (Pubitemid 43159963)
36. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-320
37. Safaeian M, Herrero R, Hildesheim A, et al. Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007;45:1447-1454 (Pubitemid 46762397)
38. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632 (Pubitemid 46986496)
39. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-313
40. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008;26 Suppl 10:K42-52.